Jane Street
ACOR

Jane Street’s Acorda Therapeutics ACOR Stock Holding History

Jane Street’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-675
Closed -$22K – 11334
2022
Q1 		$22K Buy
+675
New +$26.5K ﹤0.01% 9916
2020
Q3 		– Sell
-2,167
Closed -$191K – 8183
2020
Q2 		$191K Buy
+2,167
New +$229K ﹤0.01% 6401
2020
Q1 		– Sell
-237
Closed -$58K – 6188
2019
Q4 		$58K Sell
237
-18
-7% -$4.54K ﹤0.01% 4898
2019
Q3 		$88K Buy
+255
New +$139K ﹤0.01% 4813
2019
Q1 		– Sell
-158
Closed -$296K – 5834
2018
Q4 		$296K Sell
158
-492
-76% -$1.07M ﹤0.01% 4085
2018
Q3 		$1.53M Buy
+650
New +$2.01M ﹤0.01% 2204
2016
Q1 		– Sell
-40
Closed -$208K – 4781
2015
Q4 		$208K Buy
+40
New +$175K ﹤0.01% 3550
2014
Q4 		– Sell
-808
Closed -$3.29M – 3167
2014
Q3 		$3.29M Buy
+808
New +$3.03M 0.03% 405
2013
Q3 		– Sell
-144
Closed -$569K – 3230
2013
Q2 		$569K Buy
+144
New +$593K 0.01% 1329

Other funds holding ACOR

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $772M AUM 32.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Saltoro Capital Dallas, Texas $30K AUM 24.79% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jane Street's ACOR Position: Q2 2022 in Review

Jane Street sold out of Acorda Therapeutics (ACOR) in Q2 2022, closing a stake of 675 shares — an estimated $22K sold.

Jane Street first reported a position in ACOR in Q2 2013 and held it in 9 quarters. The position peaked at $3.29M in Q3 2014. 32 funds tracked by Wall St. Rank hold ACOR as of Q2 2022.

  • Jane Street reported no remaining Acorda Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Jane Street sold 675 Acorda Therapeutics shares in Q2 2022, an estimated $22K.
  • Jane Street first reported a position in Acorda Therapeutics in Q2 2013 and held it in 9 quarters.
  • Jane Street's Acorda Therapeutics position peaked at $3.29M in Q3 2014.
  • 32 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2022.

Based on Jane Street's 13F filing for Q2 2022, filed 16 Aug 2022.